Awards
26 Jun 2018
Alacris awarded with quality seal “Innovative through Research”.
Alacris Theranostics was honored for the second time in a row by the “Stifterverband für die Deutsche Wissenschaft” for its research competence and innovative ability. The Stifterverband has set itself the task of investigating and evaluating the German research and innovation system. Accordingly the association carries out an annual R & D survey on behalf […]
20 May 2016
Alacris Theranostics receives seal of approval “Innovation through research”
Alacris Theranostics was honored for the second time in a row by the “Stifterverband für die Deutsche Wissenschaft” for its research competence and innovative ability. The Stifterverband has set itself the task of investigating and evaluating the German research and innovation system. Accordingly the association carries out an annual R & D survey on behalf […]
National and International funded research projects
3TR (2019 – 2026)
3TR is an Innovative Medicines Initiative (IMI) funded project that aims to provide fundamental new insights into the mechanisms of response and non-response to treatment for chronic autoimmune diseases, inflammatory bowl diseases and respiratory diseases.
iPC (2019 – 2023)
Horizon 2020 funded project, with the aim of establishing a novel cloud-based infrastructure for the personalised treatment of paediatric cancer patients.
CanPathPro (2016 – 2021)
Alacris Theranostics co-ordinated this Horizon 2020 funded project aimed at developing a combined experimental and systems biology platform for predictive modelling of cancer signalling.
TREGeneration (2015 -2021)
As part of the Horizon 2020 programme the European consortium carries out a clinical research project for the treatment of Graft versus Host Disease, a serious complication following bone marrow transplantation.
SMARTool (2016 – 2020)
Horizon 2020 funded project aimed at developing IT solutions to support clinicians in the prevention and treatment of heart disease.
Cancer ID (2015 – 2020)
A European consortium funded by the Innovative Medicines Initiative (IMI) with currently 33 partners from 13 countries aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers.
PROSEQO (2016 – 2019)
A FET-OPEN Horizon 2020 funded project, aimed at developing novel proof-of-principle technologies for high-throughput protein sequencing and single molecule DNA/RNA sequencing.
Treat20plus (2014 – 2019)
Applying a systems biology approach to predicting treatment outcome in metastatic skin cancer patients. Funded by the German Federal Ministry of Education and Research (BMBF)
SYBIL (2013 – 2017)
A large-scale inter-disciplinary consortium, funded by the FP7 programme, aimed at functional validation of genetic determinants of common and rare skeletal diseases. Results generated will enhance the mechanistic understanding of disease processes and age-related changes, and deliver new and validated therapeutic targets.
OncoTrack (2011 – 2016)
An International consortium of over 80 scientists that has launched one of Europe’s largest collaborative academic-industry research projects funded by the Innovative Medicines Initiative (IMI). The project focused on developing and validating biomarkers to provide a personalised approach to the treatment of colon cancer; a goal driven by a systems medicine approach based on in silico “Virtual Patient” models.